drugset / Trial / NCT04135690
HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus toripalimab versus hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus sorafenib in patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombus.
Timeline
- Start
- 2019-10-20
- Primary completion
- 2023-12-20
- Completion
- 2023-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sorafenib | Small molecule | 400 mg | Oral |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |
| Background | Atezolizumab | Monoclonal antibody | — | — |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Camrelizumab | Monoclonal antibody | — | — |
| Background | Rivoceranib | Small molecule | — | — |
| Background | Sintilimab | Monoclonal antibody | — | — |